TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a plate heat exchanger for heat pump cooling and heating equipment with industry-leading heat transfer performance – triple that of conventional models. Specifically, the new heat exchanger reduces the number of plate layers allowing the refrigerant charge to be reduced to approximately one-third that of conventional levels, resulting in lower environmental impact and improved safety. The
Tag: Business Wire
TOKYO–(BUSINESS WIRE)–Mitsubishi Electric Corporation (TOKYO: 6503) announced today that it has developed a plate heat exchanger for heat pump cooling and heating equipment with industry-leading heat transfer performance – triple that of conventional models. Specifically, the new heat exchanger reduces the number of plate layers allowing the refrigerant charge to be reduced to approximately one-third that of conventional levels, resulting in lower environmental impact and improved safety. The
CAMBRIDGE, England–(BUSINESS WIRE)–British technology company Signaloid today announced the appointment of three distinguished industry veterans to its advisory board and senior leadership roles, to strengthen the commercialization momentum behind its technology: Dr. Han Lee, former Global Head of Quantitative Strategies and Automated Trading for the Fixed Income Division at Morgan Stanley, Dr. Nachiketh Potlapally, former Architect at Oracle Cloud Infrastructure, and Christian Roth, former S
CAMBRIDGE, England–(BUSINESS WIRE)–British technology company Signaloid today announced the appointment of three distinguished industry veterans to its advisory board and senior leadership roles, to strengthen the commercialization momentum behind its technology: Dr. Han Lee, former Global Head of Quantitative Strategies and Automated Trading for the Fixed Income Division at Morgan Stanley, Dr. Nachiketh Potlapally, former Architect at Oracle Cloud Infrastructure, and Christian Roth, former S
WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-sm
WILMINGTON, Del.–(BUSINESS WIRE)–Updated exploratory results from the ADAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after complete tumor resection with curative intent. These results were presented today d
TOKYO–(BUSINESS WIRE)–Enhertu Demonstrated a Median 14.3 Month Progression-Free Survival as First-Line Therapy in Patients with HER2 Mutant Advanced NSCLC in DESTINY-Lung04
BANGKOK–(BUSINESS WIRE)–Black & Veatch marks more than fifteen years of working in floating LNG (FLNG) this year at Gastech 2026, showcasing dramatic liquefaction performance increases and the launch of the company’s LNG-focused infrastructure intelligence toolset, BVInfraIQ.LNG. These advancements form the basis for the company’s new Advanced Liquefaction Architecture (ALA). ALA encompasses more than 60 years of LNG experience and more than fifteen years of offshore experience achieving
BANGKOK–(BUSINESS WIRE)–Black & Veatch marks more than fifteen years of working in floating LNG (FLNG) this year at Gastech 2026, showcasing dramatic liquefaction performance increases and the launch of the company’s LNG-focused infrastructure intelligence toolset, BVInfraIQ.LNG. These advancements form the basis for the company’s new Advanced Liquefaction Architecture (ALA). ALA encompasses more than 60 years of LNG experience and more than fifteen years of offshore experience achieving
PRINCETON, N.J. & TOKYO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced results from the Phase 3 REZILIENT3 trial evaluating zipalertinib plus chemotherapy versus chemotherapy alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutation-positive non-small cell lung cancer (NSCLC). The data were presented at the International
